Kazmira Therapeutics targets market expansion with US DEA's cannabis rescheduling proposal.
Kazmira Therapeutics, a cannabis company, eyes market expansion with US DEA's cannabis rescheduling proposal from Schedule I to III. This change could boost research, accessibility, and industry acceptance. Kazmira aims to leverage this opportunity, seeking partnerships for FDA-approved cannabis therapeutics, leading to increased US manufacturing, regulatory oversight, and domestic production incentives.
April 30, 2024
4 Articles